List of Excipients in Branded Drug ICOSAPENT

« Back to Dashboard

Generic Drugs Containing ICOSAPENT

Company	Ingredient	NDC	Excipient
AvKARE	icosapent ethyl	42291-032	AMMONIA
AvKARE	icosapent ethyl	42291-032	GELATIN
AvKARE	icosapent ethyl	42291-032	GLYCERIN
AvKARE	icosapent ethyl	42291-032	MANNITOL
AvKARE	icosapent ethyl	42291-032	POLYETHYLENE GLYCOL
AvKARE	icosapent ethyl	42291-032	POLYVINYL ACETATE PHTHALATE
AvKARE	icosapent ethyl	42291-032	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in ICOSAPENT?

# Of NDCs	Excipient
3	AMMONIA
3	GELATIN
3	GLYCERIN
3	MANNITOL
3	POLYETHYLENE GLYCOL
3	POLYVINYL ACETATE PHTHALATE
3	PROPYLENE GLYCOL

Icosapent Excipient Strategy and Commercial Opportunities in 2025

Last updated: October 9, 2026

Icosapent ethyl is a high-volume, lipid-based softgel opportunity with low formulation complexity but demanding oxidation, fill-weight, capsule-shell, and bioequivalence requirements. The originator product, Vascepa, uses a gelatin-based softgel containing icosapent ethyl with glycerin, sorbitol, purified water, and titanium dioxide. The primary commercial opportunities are generic substitution, excipient-enabled stability improvements, vegetarian capsule systems, lower-cost manufacturing, and differentiated omega-3 products that preserve the FDA-approved pharmaceutical profile.

What is the pharmaceutical product and how is it formulated?

Icosapent ethyl is the ethyl ester of eicosapentaenoic acid, or EPA. It is not interchangeable from a regulatory or formulation perspective with mixtures of EPA and docosahexaenoic acid, fish-oil supplements, or omega-3-acid ethyl esters.

The FDA-approved product is marketed as Vascepa in 0.5-gram and 1-gram capsules. The approved dosing is:

Product characteristic	Vascepa specification
Active ingredient	Icosapent ethyl
Strengths	0.5 g and 1 g
Dosage form	Oral softgel capsule
Approved dose for severe hypertriglyceridemia	4 g/day
Approved cardiovascular-risk reduction dose	4 g/day
Typical administration	Two 1-g capsules twice daily with food
Originator	Amarin Pharma
FDA initial approval	July 2012
Cardiovascular-risk indication	December 2019
Principal delivery system	Gelatin softgel
Key formulation issues	Oxidation, capsule integrity, fill uniformity, dissolution, odor, and storage stability

The product contains highly purified icosapent ethyl rather than a natural triglyceride oil. That distinction reduces the need to manage multiple omega-3 components but does not eliminate sensitivity to oxygen, light, heat, and trace catalytic impurities.

What excipients are used in Vascepa capsules?

The Vascepa label identifies gelatin, glycerin, sorbitol, purified water, and titanium dioxide as inactive ingredients. The capsule fill is predominantly icosapent ethyl, while the shell provides mechanical protection and controls manufacturability [1].

Excipient	Functional role	Commercial relevance
Gelatin	Capsule-forming polymer	Provides strength, elasticity, sealing, and established softgel manufacturability
Glycerin	Plasticizer and humectant	Controls shell flexibility and reduces brittleness
Sorbitol	Plasticizer and moisture-control component	Supports shell texture and mechanical performance
Purified water	Processing and shell hydration component	Affects gelatin network formation and long-term shell behavior
Titanium dioxide	Opacifier and colorant	Reduces light exposure and supports product appearance

The excipient system is conventional. The value is in process control and stability performance rather than an unusual inactive-ingredient platform.

Why is the softgel system commercially important?

Icosapent ethyl is an oily, lipophilic active ingredient. A softgel avoids the processing burden associated with compressing a liquid or semisolid fill into a tablet. It also supports high drug loading, which is important because the daily dose is 4 grams.

A 4-gram daily regimen creates a substantial capsule burden. A manufacturer that improves fill density, reduces capsule size, or develops a robust 2-gram unit-dose format could gain a commercial advantage, although such a change would require regulatory support and new bioequivalence evidence.

How should manufacturers design an excipient strategy for icosapent ethyl?

The most effective strategy is to treat the product as an oxidation-sensitive lipid formulation rather than as a conventional oral solid.

Oxidation control

The formulation program should control:

• Dissolved oxygen in the bulk fill
• Headspace oxygen
• Peroxide and anisidine values
• Metal contamination
• Exposure to heat and light
• Residence time during compounding and encapsulation
• Oxygen transmission through packaging

The most commercially defensible approach is usually a combination of low-oxygen processing, qualified raw materials, opaque or light-resistant capsules, and protective packaging. Antioxidants may be technically useful, but they also introduce new regulatory, compatibility, flavor, and labeling issues.

A manufacturer should not assume that adding a common antioxidant automatically improves product quality. The antioxidant must be shown to control degradation without creating new impurities or changing the pharmaceutical profile.

Capsule-shell optimization

The gelatin shell is a major excipient opportunity. Shell composition affects:

• Brittleness during storage
• Seal integrity
• Leakage
• Drying time
• Dissolution
• Appearance
• Compatibility with the oily fill
• Equipment speed and yield

Vegetarian alternatives based on modified starch, carrageenan, hydroxypropyl starch, or hydroxypropyl methylcellulose could expand market access among patients who avoid animal-derived gelatin. These systems may require different water activity, drying conditions, sealing parameters, and dissolution controls.

The commercial tradeoff is clear. Gelatin is mature, inexpensive, and widely supported by contract manufacturers. Vegetarian shells can create product differentiation but may increase development cost and manufacturing risk.

Fill-phase engineering

Icosapent ethyl can be manufactured as a neat oily fill or with selected processing aids. The most attractive strategy is to preserve a high active load while improving:

• Fill-weight accuracy
• Pumpability
• Deaeration
• Encapsulation speed
• Low-temperature flow
• Uniformity across the batch

Additional excipients in the fill may create patentable or regulatory distinctions, but they can also reduce the percentage of active ingredient per capsule and increase the daily capsule count.

What excipient technologies can create commercial differentiation?

Vegetarian and allergen-positioned capsules

A non-gelatin capsule could support:

• Vegetarian product positioning
• Religious-diet compliance
• Reduced animal-origin concerns
• Access to selected institutional and international markets

The main technical barrier is matching gelatin-shell performance. Vegetarian shells often have narrower processing windows and may respond differently to humidity and temperature.

Improved oxygen-barrier packaging

Packaging may create more practical value than a complex formulation change. Options include:

• High-barrier blister packs
• Cold-form aluminum blisters
• Nitrogen-flushed bottles
• Desiccant-equipped bottles
• Low-oxygen induction seals
• Unit-dose packaging

For a lipid product, packaging claims must be supported by long-term and accelerated stability data. A package that reduces oxygen exposure can preserve peroxide limits without adding formulation excipients.

Preservative-free and antioxidant-free formulations

A purified, high-quality icosapent ethyl fill may be marketed without added antioxidants if the manufacturing process and packaging provide adequate stability. This approach simplifies the label and may reduce concerns about excipient intolerance.

The risk is that the product becomes more dependent on raw-material quality and packaging controls. A manufacturer would need tight specifications for peroxide value, water content, metals, and degradation products.

Smaller or easier-to-swallow dosage forms

The current 1-gram capsule creates a four-capsule daily regimen. Smaller capsules may improve swallowability but increase capsule count. Larger capsules could reduce pill burden but may worsen patient acceptability and create additional bioequivalence and manufacturing challenges.

An alternative opportunity is a higher-strength unit-dose softgel, sachet, or lipid-based oral delivery system. Such products would not automatically qualify as generics and could require a new drug application or supplemental regulatory pathway.

What FDA regulatory requirements apply to icosapent excipients?

Generic icosapent ethyl products generally must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. The key questions are whether the dosage form, strength, route, active ingredient, and performance are equivalent and whether excipient differences affect safety or absorption.

The FDA’s ANDA framework permits differences in inactive ingredients when those differences do not affect equivalence, safety, or performance. For a lipid-filled softgel, the sponsor must control more than assay and dissolution. Critical development areas include:

Development area	Risk
Capsule-shell composition	Different dissolution, leakage, or stability profile
Fill viscosity	Inconsistent encapsulation and fill weight
Oxygen exposure	Oxidation and impurity formation
Particle or droplet behavior	Potential impact on dissolution and absorption
Food effect	Icosapent ethyl is administered with food
Capsule size	Patient acceptability and swallowability
Packaging	Stability failure despite acceptable initial release
Raw-material variability	Peroxide, water, or metal contamination

The FDA label states that Vascepa should be taken with food. Food-effect performance is therefore commercially relevant when a manufacturer changes the fill composition or capsule shell [1].

What patents protect icosapent ethyl and its formulation?

The most important patent risks historically involved composition claims, cardiovascular-risk-reduction methods, and treatment methods for elevated triglycerides. Patent scope has varied by jurisdiction and by the specific patent family.

Patent category	Commercial relevance
Purified EPA or icosapent ethyl composition	Can restrict supply of highly purified active ingredient
Cardiovascular-risk-reduction method	Historically important after the 2019 label expansion
Hypertriglyceridemia treatment method	Relevant to the original FDA indication
Capsule and formulation claims	Can affect softgel composition and manufacturing design
Manufacturing claims	May restrict purification, esterification, or quality-control processes

Amarin disclosed multiple U.S. patents covering Vascepa and pursued patent litigation against generic applicants that filed Paragraph IV certifications. The Federal Circuit’s 2020 decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. invalidated key patents covering the cardiovascular-risk-reduction indication, holding the asserted claims obvious [2].

That decision materially weakened method-of-use protection. It did not eliminate all possible risks involving formulation, manufacturing, confidential know-how, regulatory exclusivity, or foreign rights.

What is the Orange Book status of Vascepa?

Vascepa has been listed in the FDA Orange Book with patents covering the approved product and methods of use. Orange Book listings can change through patent expiration, delisting, litigation, or administrative updates. Generic applicants must evaluate the current listing and certify against each applicable patent under the ANDA process [3].

The relevant business conclusion is that the strongest historical barrier was the branded cardiovascular indication patent estate, not the basic gelatin-glycerin-sorbitol softgel architecture. Excipient changes can support design-around positions, but they do not independently eliminate method-of-use or active-ingredient patent exposure.

When did icosapent ethyl lose exclusivity?

Vascepa’s five-year new chemical entity exclusivity expired before the later cardiovascular indication was approved. The 2019 cardiovascular indication generated regulatory exclusivity tied to the clinical investigation supporting that change, but patent protection became the more significant commercial barrier.

The product’s commercial exclusivity timeline is:

Event	Date
FDA approval for severe hypertriglyceridemia	July 2012
NCE exclusivity period	Generally expired in 2017
Cardiovascular indication approval	December 2019
Key cardiovascular patent litigation decision	May 2020
Generic market entry activity	Began after patent settlements and approvals

Generic entry timing depended on applicant-specific Paragraph IV certifications, litigation outcomes, settlement terms, and FDA approval status. Regulatory approval alone did not guarantee immediate broad substitution if commercial settlements limited the approved indication or launch date.

Which companies are challenging or competing with Vascepa?

The competitive landscape has several layers.

Generic icosapent ethyl manufacturers

Generic competition has involved companies filing ANDAs and challenging Amarin patents. Major generic pharmaceutical companies, including Hikma and Teva, have been associated with U.S. generic icosapent ethyl activity. The precise commercial status of each applicant depends on FDA approval, launch decisions, settlement restrictions, and product labeling.

Alternative prescription omega-3 products

Vascepa competes with:

• Omega-3-acid ethyl esters
• Fenofibrate
• Generic statins as background therapy
• Prescription EPA products outside the United States
• Nutraceutical fish-oil products

Icosapent ethyl is differentiated by its EPA-only composition and the REDUCE-IT cardiovascular-outcomes data. The REDUCE-IT trial reported a significant reduction in major cardiovascular events in statin-treated patients with elevated triglycerides and controlled low-density lipoprotein cholesterol [4].

Nutraceutical products

Dietary supplements generally compete on price and availability but do not have the same approved cardiovascular-risk-reduction indication. Their composition, purity, manufacturing controls, and clinical evidence can differ materially from prescription icosapent ethyl.

What commercial opportunities exist for excipient suppliers?

The largest opportunity is not a single novel excipient. It is a qualification and supply platform for high-volume lipid softgels.

Priority supplier opportunities

1. Vegetarian softgel polymers with validated oxygen and moisture performance.
2. High-barrier blister and bottle systems.
3. Low-peroxide, low-metal processing aids.
4. Capsule-shell plasticizer systems optimized for lipid fills.
5. Nitrogen-processing and deaeration equipment.
6. Stability-indicating analytical packages for oxidation products.
7. Contract development and manufacturing for generic softgels.
8. Excipient systems that support high-speed encapsulation with low leakage.

Excipient suppliers that can provide regulatory documentation, global compendial compliance, extractables and leachables data, and stable supply are better positioned than suppliers offering an unqualified substitute.

How strong is the patent estate for an excipient-based icosapent product?

The patent position is moderate for the basic product architecture and weaker for broad method-of-use claims after the Federal Circuit’s invalidation of key Amarin patents. A new excipient system could improve freedom to operate, but its protection would depend on genuinely novel composition, shell, packaging, or process claims.

A defensible formulation patent would need to claim measurable technical advantages, such as:

• Lower peroxide formation after accelerated storage
• Defined impurity limits
• Improved capsule integrity
• Reduced oxygen transmission
• Enhanced dissolution under fed-state conditions
• Lower capsule-shell migration
• A specific shell composition compatible with icosapent ethyl

A claim directed only to substituting one conventional plasticizer for another is likely to face obviousness and enablement challenges.

What generic launch risks exist for icosapent ethyl?

The main risks are:

Risk	Impact
Patent litigation	Delays launch or restricts indication
Food-effect differences	Creates bioequivalence risk
Oxidation during scale-up	Causes stability failures
Capsule leakage	Increases rejects and recalls
Shell incompatibility	Changes dissolution or appearance
API supply concentration	Limits manufacturing flexibility
Price erosion	Reduces return on formulation investment
Indication carve-outs	Restricts labeling and substitution
Packaging cost	Reduces margin advantage
Patient adherence	Four-capsule daily regimen limits retention

The likely generic strategy is a conventional gelatin softgel with a high active load, supported by a low-cost manufacturing process and protected packaging. More differentiated products may command higher prices but face greater regulatory and development burdens.

How does icosapent ethyl compare with omega-3-acid ethyl esters?

Attribute	Icosapent ethyl	Omega-3-acid ethyl esters
Principal active	EPA ethyl ester	EPA and DHA ethyl esters
Cardiovascular indication	Approved for selected high-risk patients	Product-specific; not equivalent
Dosage form	Softgel	Usually softgel
Capsule burden	High at 4 g/day	Often high at 4 g/day
Excipient strategy	Oxidation control and high EPA loading	Multi-component oil stability
DHA-related effects	No DHA contribution	DHA may raise LDL cholesterol in some settings
Generic opportunity	Established	Established across multiple products
Product differentiation	Purity, outcomes data, shell, packaging	Composition and indication

The absence of DHA simplifies the active phase but increases the importance of maintaining EPA purity and controlling oxidation-related impurities.

Key Takeaways

• Icosapent ethyl is a high-dose oily softgel product with a conventional but technically demanding excipient system.
• Vascepa uses gelatin, glycerin, sorbitol, purified water, and titanium dioxide in the capsule shell.
• The strongest formulation opportunities involve oxidation control, oxygen-barrier packaging, vegetarian shells, and high-speed encapsulation.
• Generic value depends more on manufacturing yield, stability, API quality, and litigation strategy than on novel excipient selection.
• Key historical cardiovascular method-of-use patents were weakened by the 2020 Federal Circuit decision in Hikma v. Amarin.
• A formulation patent is more defensible when it links a defined excipient system to measurable stability, dissolution, or capsule-integrity benefits.
• The commercial market includes generic icosapent ethyl, prescription omega-3 alternatives, fibrates, statins, and dietary supplements.
• Excipient suppliers can capture value through qualified shell polymers, packaging systems, oxidation-control technologies, and regulatory support.

FAQs about icosapent ethyl excipients and market opportunities

Can icosapent ethyl be made as a tablet?

A tablet is technically possible but commercially unattractive for a liquid, high-dose oily active. A softgel provides higher active loading and simpler containment. A tablet or solid lipid system would require substantial formulation development and bioequivalence evidence.

Is gelatin essential for icosapent ethyl capsules?

No. Gelatin is the established shell material, but vegetarian polymers may be used if they provide equivalent capsule integrity, dissolution, stability, and manufacturing performance.

Does icosapent ethyl require an antioxidant?

Not necessarily. A formulation may achieve acceptable stability through purified API, low-oxygen processing, controlled metals, suitable shell materials, and protective packaging. An antioxidant can be considered but must be justified by stability and impurity data.

Can a generic use different inactive ingredients from Vascepa?

Yes, subject to FDA requirements. The alternative excipients must not compromise pharmaceutical equivalence, bioequivalence, safety, stability, or product performance.

What is the most attractive near-term commercial opportunity?

The strongest near-term opportunity is a cost-efficient generic softgel using a conventional gelatin shell, validated oxidation controls, and high-barrier packaging. Vegetarian capsules and novel delivery systems offer greater differentiation but carry higher regulatory and technical risk.

References

1. U.S. Food and Drug Administration. (2024). Vascepa (icosapent ethyl) prescribing information.
2. United States Court of Appeals for the Federal Circuit. (2020). Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., 946 F.3d 1368.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, J.-C., & Ballantyne, C. M. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine, 380(1), 11-22. https://doi.org/10.1056/NEJMoa1812792